BioLife Sciences Inc
BioLife Sciences Inc. develops, licenses, and commercializes products and technologies for the healthcare, beauty, and food and beverage industries. It also offers orthomolecular products. The company is based in Henderson, Nevada.
BioLife Sciences Inc (BLFE) - Net Assets
Latest net assets as of February 2022: $-109.57 USD
Based on the latest financial reports, BioLife Sciences Inc (BLFE) has net assets worth $-109.57 USD as of February 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.04K) and total liabilities ($1.15K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-109.57 |
| % of Total Assets | -10.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1257.29% |
| 10-Year Change | N/A |
| Growth Volatility | 446.91 |
BioLife Sciences Inc - Net Assets Trend (2004–2020)
This chart illustrates how BioLife Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioLife Sciences Inc (2004–2020)
The table below shows the annual net assets of BioLife Sciences Inc from 2004 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-11-30 | $-689.58K | -59655.89% |
| 2019-11-30 | $-1.15K | +99.48% |
| 2018-11-30 | $-220.87K | -20.63% |
| 2017-11-30 | $-183.10K | -407.29% |
| 2007-11-30 | $59.59K | -76.21% |
| 2006-11-30 | $250.44K | +800.01% |
| 2005-11-30 | $27.83K | -60.22% |
| 2004-11-30 | $69.95K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioLife Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 122772100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.49K | % |
| Other Comprehensive Income | $-35.86K | % |
| Other Components | $609.68K | % |
| Total Equity | $-689.58K | 100.00% |
BioLife Sciences Inc Competitors by Market Cap
The table below lists competitors of BioLife Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beard Co
PINK:BRCOQ
|
$0.94 |
|
Infusion Brands International Inc
PINK:INBI
|
$0.94 |
|
Montague International Holding Ltd
PINK:MIHL
|
$0.94 |
|
Hybrid Energy Holdin
PINK:HYBE
|
$0.94 |
|
Novation Hldgs Inc.
PINK:NOHO
|
$0.94 |
|
EPIC Corp
PINK:EPOR
|
$0.94 |
|
RBC Life Sciences Inc
PINK:RBCL
|
$0.94 |
|
Liberty International Holding Corp
PINK:PDPG
|
$0.94 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLife Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -1,154 to -689,583, a change of -688,429.
- Net loss of 1,268,000 reduced equity.
- Other comprehensive income decreased equity by 35,857.
- Other factors increased equity by 615,428.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.27 Million | -183.88% |
| Other Comprehensive Income | $-35.86K | -5.2% |
| Other Changes | $615.43K | +89.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioLife Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-11-30 | $47.65 | $0.00 | x |
| 2005-11-30 | $17.92 | $0.00 | x |
| 2006-11-30 | $142.05 | $0.00 | x |
| 2007-11-30 | $25.61 | $0.00 | x |
| 2015-11-30 | $-0.30 | $0.00 | x |
| 2016-11-30 | $-0.35 | $0.00 | x |
| 2017-11-30 | $-0.04 | $0.00 | x |
| 2018-11-30 | $-0.01 | $0.00 | x |
| 2019-11-30 | $0.00 | $0.00 | x |
| 2020-11-30 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLife Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -307.99%
- • Asset Turnover: 5.66x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-898.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -25.53% | 0.00% | 0.00x | 1.24x | $-24.86K |
| 2005 | -5412.20% | -25555.74% | 0.00x | 59.37x | $-1.51 Million |
| 2006 | -116.20% | -4.51% | 1.86x | 13.87x | $-316.04K |
| 2007 | -3433.69% | -23.78% | 2.29x | 63.13x | $-2.05 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.18K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.56K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-321.69K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.63K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.02K |
| 2020 | 0.00% | -307.99% | 5.66x | 0.00x | $-1.20 Million |
Industry Comparison
This section compares BioLife Sciences Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLife Sciences Inc (BLFE) | $-109.57 | -25.53% | N/A | $0.94 |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |